Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms.

ABSTRACT:

Purpose

Early diagnosis of cancer is critical for improving patient outcomes, but cancers may be hard to diagnose if patients present with nonspecific signs and symptoms. We have previously shown that nuclear magnetic resonance (NMR) metabolomics analysis can detect cancer in animal models and distinguish between differing metastatic disease burdens. Here, we hypothesized that biomarkers within the blood metabolome could identify cancers within a mixed population of patients referred from primary care with nonspecific symptoms, the so-called "low-risk, but not no-risk" patient group, as well as distinguishing between those with and without metastatic disease.

Experimental design

Patients (n = 304 comprising modeling, n = 192, and test, n = 92) were recruited from 2017 to 201

SUBMITTER: Larkin JR 

PROVIDER: S-EPMC7613224 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature